An analysis of clinical correlations showed that FAP, VCAN, N-cadherin, and Vimentin expression levels were significantly higher in stage III-IV BLCA compared to stage I–II (Fig. 9C), and that high-grade BLCA exhibited greater expression than low-grade (Fig. 9D). The gene discussed is FAP; the disease is bladder transitional cell carcinoma.